Update of the Overview of upcoming CBER Guidelines in 2024
![Modern Microbiology Laboratory - Live Online Training](files/eca/userImages/training.img/Z-ECA-Modern-Microbiology-Laboratory-Live-Online.jpg)
Recommendation
10-12 December 2024
Mastering the challenges of classic and modern microbiological methods
At regular intervals, the FDA's Center for Biologics Evaluation and Research (CBER) publishes an overview of the new guidelines planned for publication in the current financial year in areas in which no documents currently exist, of guidelines that exist but are now to be revised and of guidelines of which drafts already exist and which can now be finalised following evaluation of the comments received. The list represents a plan, a declaration of intent, but is not binding and topics may be omitted for the time being and guidelines on other topics may be revised.
Below you will find an overview of the guidelines mentioned.
Category Blood and Blood Components
- Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma; Guidance for Industry
- Considerations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method; Draft Guidance for Industry
- Collection of Platelets by Automated Methods; Draft Guidance for Industry
- Blood Pressure and Pulse Donor Eligibility Requirements; Compliance Policy; Guidance for Industry
- Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen; Draft Guidance for Industry
- Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria; Draft Guidance for Industry
Category Therpeutical Products
- Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry (Published 1/30/2024)
- Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Guidance for Industry (Published 1/30/2024)
- Frequently Asked Questions — Cell and Gene Therapy Products; Draft Guidance for Industry
- Considerations for the Use of Human- and Animal- Derived Materials and Components in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products; Draft Guidance for Industry (Published 4/30/2024)
- Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products; Draft Guidance for Industry (Published 4/30/2024)
- Accelerated Approval of Human Gene Therapy Products for Rare Diseases; Draft Guidance for Industry
- Use of Platform Technologies in Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry
- Potency Assessment of Therapeutic Vaccines; Draft Guidance for Industry
- Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Guidance for Industry
- Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Guidance for Industry
- Recommendations to Reduce the Risk of Transmission of Human Immunodeficiency Virus (HIV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry
- Recommendations to Reduce the Risk of Transmission of Hepatitis C Virus (HCV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry
- Recommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry
- Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry
Category Other
- Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center for Biologics Evaluation and Research Submissions (Published 6/5/2024)
The complete agenda of the CBER can you find directly at CBERs website.
Related GMP News
14.08.2024A further Step for the SoHO Regulation
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials
22.05.2024New FDA Draft Guideline regarding Safety Testing of human allogeneic Cells
07.05.2024Final Approval of SoHO Regulation
07.05.2024FDA Warning Letter to a Biotechnology Company in China